Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer
This is a single-arm, prospective, Phase II clinical trial designed to assess the efficacy and safety of QL1706 in combination with olaparib in patients with recurrent or metastatic triple-negative breast cancer (TNBC) harboring homologous recombination repair deficiency (HRD) who have received prior therapy.
Triple-Negative Breast Cancer (TNBC)
DRUG: QL1706 Plus Olaparib
Progression-Free Survival (PFS) - investigator assessment, Up to 2 years
Objective response rate (ORR) - Investigator assessment, Up to 2 years|Duration of response (DOR) - Investigator assessment, Up to 2 years|Overall survival (OS), Up to 5 years|Number of participants with adverse events (AEs), Serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs), Up to 5 years
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With a Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) of ≥1%, PFS was determined in participants who had a PD-L1 CPS of ≥1% as measured by immunohistochemistry assay., Up to 2 years
This is a single-arm, prospective, Phase II clinical trial designed to assess the efficacy and safety of QL1706 in combination with olaparib in patients with recurrent or metastatic triple-negative breast cancer (TNBC) harboring homologous recombination repair deficiency (HRD) who have received prior therapy.